NanoInk, a technology-based company, is specialized in nanometer-scale manufacturing and applications development for life science and semiconductor industries. The company currently owns 140 patents and applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign. The company’s Dip Pen Nanolithography, a patented and proprietary nanofabrication technology, enables scientists to create nanoscale structures from a variety of materials.
The new division is expected to provide reliable, renewable source of differentiated adult stem cells, through the application of Dip Pen Nanolithography technology.
Haris Jamil, vice president of stem cell research at NanoInk, will head the new division. He said that the project is one of the promising areas of scientific research.
James Hussey, CEO of NanoInk, said: NanoInk now has solutions to the problems that have limited the utility of adult stem cells. Our technology will lead to faster and more efficient drug discovery and development processes, with substantial cost savings.
In addition, this technology will offer opportunities in clinical diagnostics and will represent a giant step toward delivering on the promise of regenerative medicine.